INSM INSM
Company Profile ↓Company Overview
INSM (INSM) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 31.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $606.42M (+66.7% YoY); net profit $-1.28B.
- Trailing 12 Months Year-on-year growth — revenue +66.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.16% |
| 1 Year: | 66.73% |
Stock Price Performance
| 1 Year: | -10.99% |
| 6 Months: | -36.99% |
| 3 Months: | -28.99% |
| 1 Month: | -12.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 31.2% over 5 years.
CONS
- Trading 53.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.84M | 21.90M | 29.97M | 38.88M | 45.71M | 36.86M | 42.49M | 43.64M | 40.21M | 45.37M | 46.76M | 53.11M | 65.22M | 67.73M | 65.21M | 77.23M | 79.07M | 75.50M | 90.34M | 93.42M | 92.82M | 107.42M | 142.34M | 305.96M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 7.41M | 17.75M | 25.05M | 32.45M | 37.00M | 28.42M | 32.55M | 33.02M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -23.07M | -26.71M | -27.95M | -30.25M | -32.59M | -33.07M | -36.13M | -37.15M | -67.05M | -35.97M | -43.52M | -44.08M | -65.35M | -62.75M | -72.88M | -83.98M | -87.72M | -69.51M | -62.17M | -56.49M | -47.08M | -60.36M | -54.11M | -56.22M | -83.83M | -88.57M | -103.62M | -89.83M | -88.32M | -127.70M | -148.16M | -235.53M | -147.67M | -145.50M | -288.90M | -213.43M | -248.14M | -312.88M | -366.00M | -153.32M |
| Net Income | -17.65M | -27.37M | -28.61M | -30.96M | -31.25M | -33.53M | -36.58M | -37.76M | -68.40M | -37.41M | -44.67M | -45.18M | -65.38M | -68.52M | -76.44M | -87.74M | -91.57M | -74.15M | -66.51M | -60.68M | -52.99M | -66.36M | -61.85M | -63.66M | -91.64M | -117.32M | -112.71M | -94.62M | -95.64M | -131.15M | -159.76M | -244.81M | -158.93M | -157.09M | -300.61M | -220.52M | -256.58M | -321.69M | -370.02M | -163.56M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.64 | -0.63 | -0.89 | -1.07 | -0.96 | -0.80 | -0.80 | -1.09 | -1.17 | -1.78 | -1.11 | -1.06 | -1.94 | -1.27 | -1.42 | -1.70 | -1.75 | -0.76 |
| R&D Expense | - | 17.16M | 18.25M | 19.22M | - | 20.55M | 23.87M | 23.43M | - | 22.25M | 26.87M | 26.68M | - | 30.10M | 35.72M | 39.54M | - | 31.20M | 33.54M | 34.34M | - | 36.18M | 35.75M | 41.41M | 61.39M | 64.66M | 70.35M | 84.36M | 88.53M | 99.87M | 127.86M | 196.97M | 109.15M | 121.08M | 146.75M | 150.81M | 152.58M | 177.19M | 186.41M | 209.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.37M | 6.92M | 4.42M | 0 | 11.50M | - | 0 | 0 | 0 | 9.84M | 136.47M | 164.41M | 188.46M | 245.36M | 305.21M | 363.71M | 606.42M |
| Gross Profit | - | - | - | - | - | - | - | - | 0 | 7.41M | 112.25M | - | - | - | - | - | - |
| Operating Income | -8.67M | -8.09M | -61.72M | -42.44M | -55.02M | -87.36M | -117.49M | -173.40M | -188.92M | -307.34M | -235.25M | -265.23M | -375.09M | -457.32M | -709.63M | -878.25M | -1.25B |
| Net Income | 118.35M | -6.43M | -59.66M | -41.37M | -56.07M | -79.16M | -118.18M | -176.27M | -192.65M | -324.28M | -254.34M | -294.09M | -434.65M | -481.53M | -749.57M | -913.77M | -1.28B |
| Diluted EPS | 9.30 | -0.49 | -2.95 | - | - | - | - | - | - | - | -3.01 | -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 |
| R&D Expense | 9.21M | 4.70M | 28.62M | 29.78M | 44.28M | 56.29M | 74.28M | 122.72M | 109.75M | 145.28M | 131.71M | 181.16M | 272.74M | 397.52M | 571.01M | 598.37M | 771.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 196.26M | 139.83M | 153.56M | 176.50M | 230.86M | 356.56M | 237.96M | 462.05M | 604.56M | 742.30M | 796.15M | 1.24B | 1.66B | 1.33B | 2.03B | 2.26B |
| Total Equity | -2.82M | 123.91M | 192.84M | 134.27M | 120.88M | 143.32M | 186.24M | 311.70M | 154.48M | 361.06M | 208.27M | 261.67M | 275.88M | 410.47M | 87.95M | -331.92M | 285.38M | 738.98M |
| Cash & Equivalents | - | - | 10.74M | 14.85M | 90.78M | 113.89M | 159.23M | 282.88M | 162.59M | 381.17M | 495.07M | 487.43M | 532.76M | 716.78M | 1.07B | 482.37M | 555.03M | 510.44M |
| Long Term Debt | - | - | - | 0 | 16.22M | 16.34M | 24.86M | 22.03M | 54.79M | 55.57M | 316.56M | 335.94M | 356.32M | 566.59M | 1.13B | 1.16B | 1.10B | 540.96M |
| Total Liabilities | - | - | 3.42M | 5.57M | 32.68M | 33.17M | 44.63M | 44.86M | 83.47M | 100.99M | 396.29M | 480.62M | 520.27M | 833.04M | 1.57B | 1.66B | 1.74B | 1.53B |
| Current Liabilities | - | - | 3.34M | 4.48M | 15.75M | 16.46M | 19.63M | 22.26M | 27.99M | 44.66M | 79.73M | 85.24M | 118.81M | 135.17M | 190.24M | 225.63M | 297.53M | 468.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.01M | -7.72M | -30.20M | -31.01M | - | - | -100.70M | -146.71M | -159.62M | -257.98M | -250.65M | -219.35M | -363.30M | -400.44M | -536.25M | -683.88M | -935.01M |
| Investing Cash Flow | 18.73M | 5.96M | 34.36M | 61.52M | - | - | -3.45M | -4.20M | -3.00M | -14.81M | -42.27M | -6.82M | -64.28M | -34.58M | -223.60M | -583.17M | -64.58M |
| Financing Cash Flow | 2.88M | -233.00K | -50.00K | 45.42M | - | - | 227.80M | 30.67M | 381.09M | 386.74M | 285.28M | 271.00M | 612.55M | 793.27M | 168.44M | 1.34B | 954.07M |
| Capital Expenditure | -0 | -0 | -979.00K | -290.00K | -826.00K | -5.35M | -3.45M | -4.20M | -3.00M | -13.09M | -42.27M | -6.24M | -7.29M | -9.88M | -13.29M | -21.92M | -32.56M |
| Free Cash Flow | -11.01M | -7.72M | -31.18M | -31.30M | - | - | -104.15M | -150.91M | -162.62M | -271.07M | -292.92M | -225.59M | -370.59M | -410.32M | -549.53M | -705.80M | -967.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 75.4% | 82.3% | - | - | - | - | - | - |
| Operating Margin % | -83.6% | -116.9% | -1,397.3% | - | -478.4% | - | - | - | - | -3,124.9% | -172.4% | -161.3% | -199.0% | -186.4% | -232.5% | -241.5% | -205.6% |
| Net Margin % | 1,140.9% | -93.0% | -1,350.8% | - | -487.6% | - | - | - | - | -3,297.2% | -186.4% | -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| ROE % | 95.5% | -3.3% | -44.4% | -34.2% | -39.1% | -42.5% | -37.9% | -114.1% | -53.4% | -155.7% | -97.2% | -106.6% | -105.9% | -547.5% | 225.8% | -320.2% | -172.8% |
| ROCE % | - | -4.2% | -45.6% | -30.8% | -34.4% | -41.4% | -35.1% | -82.6% | -45.3% | -58.6% | -35.8% | -39.2% | -33.8% | -31.2% | -64.3% | -50.8% | -69.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INSM
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR1ZURlFWZTNjSlZJUHFwVWtmSnlxVmQ5NkJvSjY0bjk1OXVpWlVTaDZwSm5hVkRWbWFJdnhUVWQtY3NvWTAxZDFJeGxJMWpwX1BiTWY3MXRSblpTaHRGbThibmN4OGQ1R3E4OENLeVZBSjB6aEhnMkJQS1ZHaTZCVGVJQ01TVE5QVzVYaV…
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQdWRWaENHclhEMThWMnBBbWFReHd3MTNIT3FiZV8wc09xMGc1WVpUT0hFNnRCSzNTMFJfdmJfMjk3UjR6YmZHbVRsZUlqUGJEcDMzbUNOWVdWX0FlQnlURXFZYXNDZUJmWTRqTzFHVXVJdHVBYm9MSTVzQUVOUElyUUs5NXJudGIydUN5M0…
INSM Looks 46.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxORURhN2hNaWlvdHR5eHBRR1MtWjFMekwyV1R1djlJTVFNYWo4VUFjZllvY2k4cDRqenNJeFUxMmRBQWNsdjJ6Z2NQcE9EWDRCYzhmWUNldVYybkRlSUVFSmxTYUEycVBsU2hoWmloLTJzb05ESVJrTDItN3JwRFdoWDEzN3J6cU5OVi1wbD…
Insmed earnings up next: Can Brinsupri hit $285M in Q2? - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQUGo3Nmd0NXQ5Q1VVOXFvU2JPUU1nSVZBc0RCWFAxbzVkT3NVUDBncENEejlUYmhWVENPMHZzU3diTWx0RGZvakZQYUVOcThZV1ByZUZ5NEVtTnBsek5LVnc4V2s5aVRUY2Y3SzFFUXJmNWRUYmZzVHVrSll3b1Q1R0MtWXNfX2pvdG5kMl…
Insmed Stock And 2 Healthcare Names To Watch As DOJ Uncertainty Builds - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZU5GOVRHbEFHeTJpTzFidHFVWWR6YWNvdmZ4bjJrMWxWU3RhdkRhT3RRMWlfSjl6Z1h1SmtZVkhkTlJWS0I0R1hDZW9fdjY0Nm1VOHF2RWFuVjdYNlEtRU5jYVlPMU5SRDg2a2NQRjlHTTVhQ2hCWDNabldMNjdfbkhhV3lRY0JDN3FEdF…
Insmed Slips as Traders Appear to Await Earnings Despite Recent Positive Pipeline Updates - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNdHBwSEoya0JmQlVORTN4ZV9ndkxuNmZCbjIxZC1YaUpmLWtDN3EzNUUwY0FNMG5TVDBkQkFNenAtUHlXMWVpd25hdHpweG5LOXNtRFc4ZU1UZHpidU5NaWJjVFNZTnVnU0FWME13QXVXUjhnWTJQNXk2YlRXVW15Ui11SlNyME10WFlNVn…
INSM — Frequently Asked Questions
What is the current share price of INSM?
As of 2026-08-05 17:25 PDT, INSM trades at $99.02 on NASDAQ/NYSE. Its 52-week range is $91.88 to $211.41.
What is the P/E ratio of INSM?
INSM trades at a trailing price-to-earnings (P/E) ratio of -15.42.
Is INSM a good stock to buy?
This page provides a data-driven analysis of INSM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.